Zipant-DSR Capsule is a combined pharmaceutical formulation containing Domperidone 30 mg and Pantoprazole 40 mg, designed to manage gastrointestinal disorders effectively. Domperidone, a dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and discomfort associated with delayed gastric emptying and gastroparesis. Pantoprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, providing relief from acid-related conditions including gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The synergistic action of these two agents in Zipant-DSR Capsule offers comprehensive management of upper gastrointestinal symptoms by addressing both motility and acid secretion abnormalities. This combination is particularly beneficial in patients presenting with dyspepsia, reflux symptoms, or functional gastrointestinal disorders where acid suppression and enhanced gastric motility are warranted. Zipant-DSR should be administered under medical supervision, with dosage adjustments based on clinical response and patient tolerance. Caution is advised in patients with cardiac arrhythmias, hepatic impairment, or known hypersensitivity to either component. Adverse effects may include headache, dry mouth, abdominal cramps, or diarrhea. Regular monitoring is recommended during prolonged therapy.